The FDA officially announced semaglutide on shortage in March 2022, followed by tirzepatide and dulaglutide in December 2022, and liraglutide in July 2023.(8) Even today, two years later, the supply of these medications remains sparse
Biochim Et Biophys Acta (BBA) - Gene Struct Expression
doi: 10.3390/biom13091264, 90
More serious warning signs include shallow breathing, inability to have a bowel movement for more than three days, unrelenting abdominal pain, or confusion
Hiu qu ca sn phm tu thuc vo c a v kh nng hp th ca tng ngi l khc nhau.
Using PROMs for routine symptom assessment can help monitor these changes and support clinical decision-making